These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 36199981

  • 1. The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Based on FOLFIRI for Advanced Intrahepatic Cholangiocarcinoma as Second-Line and Successive Treatment: A Real-World Study.
    Huang P, Huang X, Zhou Y, Yang G, Sun Q, Shi G, Chen Y.
    Can J Gastroenterol Hepatol; 2022; 2022():9680933. PubMed ID: 36199981
    [Abstract] [Full Text] [Related]

  • 2. Potential efficacy of hepatic arterial infusion chemotherapy using gemcitabine, cisplatin, and 5-fluorouracil for intrahepatic cholangiocarcinoma.
    Ishii M, Itano O, Morinaga J, Shirakawa H, Itano S.
    PLoS One; 2022; 17(4):e0266707. PubMed ID: 35452492
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy analysis of HAIC combined with lenvatinib plus PD1 inhibitor vs. first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma.
    Lin Z, Zou X, Hu X, Huang D, Chen Y, Lin J, Li X, Zhang J.
    Sci Rep; 2024 Oct 14; 14(1):23961. PubMed ID: 39397104
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion of oxaliplatin and raltitrexed versus oxaliplatin, 5-fluorouracil and leucovorin for intermediate and advanced hepatocellular carcinoma: A retrospective study.
    Zang M, Hu X, Yuan G, Li R, Li W, Pang H, Li Q, Chen J.
    Int Immunopharmacol; 2023 Dec 14; 125(Pt A):111019. PubMed ID: 37879230
    [Abstract] [Full Text] [Related]

  • 7. [Analysis of the efficacy and safety of hepatic arterial infusion chemotherapy for unresectable hepatitis B-related intrahepatic cholangiocarcinoma].
    He MR, Zheng ZK, Wu TQ, Chen MS, Zhou ZG.
    Zhonghua Wai Ke Za Zhi; 2024 Apr 01; 62(4):309-315. PubMed ID: 38432672
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clinical outcomes of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and anti-PD-1 immunotherapy for unresectable intrahepatic cholangiocarcinoma.
    Zhang N, Yu BR, Wang YX, Zhao YM, Zhou JM, Wang M, Wang LR, Lin ZH, Zhang T, Wang L.
    J Dig Dis; 2022 Aug 01; 23(8-9):535-545. PubMed ID: 36148493
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of lenvatinib plus durvalumab combined with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma.
    Zhao R, Zhou J, Miao Z, Xiong X, Wei W, Li S, Guo R.
    Front Immunol; 2024 Aug 01; 15():1397827. PubMed ID: 38799453
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Effectiveness of systemic chemotherapy of GEM+CBDCA+5-FU/LV and hepatic arterial infusion of CDDP in a case of advanced, combined hepatocellular-cholangiocarcinoma with multiple lung metastases].
    Tani S, Murata S, Tamura M, Fukunaga K, Morita M, Hirata Y, Iida H, Kakuno A, Nishigami T, Yamanaka N.
    Nihon Shokakibyo Gakkai Zasshi; 2011 Nov 01; 108(11):1892-901. PubMed ID: 22056711
    [Abstract] [Full Text] [Related]

  • 15. Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC).
    Kehmann L, Berres ML, Gonzalez-Carmona M, Modest DP, Mohr R, Wree A, Venerito M, Strassburg C, Keitel V, Trautwein C, Luedde T, Roderburg C.
    BMC Cancer; 2023 May 22; 23(1):470. PubMed ID: 37217885
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Systemic Chemotherapy with or without Hepatic Arterial Infusion Chemotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Oligometastasis: A Propensity Score-Matched Analysis.
    Li Z, Xu R, Chang X, Sun P.
    J Vasc Interv Radiol; 2024 Mar 22; 35(3):416-427.e17. PubMed ID: 38008375
    [Abstract] [Full Text] [Related]

  • 18. [Preliminary clinical use of hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab in the treatment of unresectable intrahepatic cholangiocarcinoma].
    Zhou BJ, Wang WS, Yin Y, Yang J, Zhu XL, Ni CF.
    Zhonghua Nei Ke Za Zhi; 2024 Aug 01; 63(8):769-775. PubMed ID: 39069865
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.